Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
作者信息
Aomar-Millán Ismael F, Salvatierra Juan, Raya Álvarez Enrique
机构信息
Servicio de Medicina Interna, Hospital Universitario Clínico San Cecilio, Granada, España; Instituto de investigación biosanitaria de Granada ibs.Granada, Granada, España.
Servicio de Reumatología, Hospital Universitario Clínico San Cecilio, Granada, España; Instituto de investigación biosanitaria de Granada ibs.Granada, Granada, España.
出版信息
Med Clin (Barc). 2022 Oct 28;159(8):e54. doi: 10.1016/j.medcli.2022.04.018. Epub 2022 Jul 20.
Abstract
摘要
相似文献
1
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.托珠单抗对比标准治疗方案对中度至重度COVID-19肺炎成年住院患者的疗效
Med Clin (Barc). 2022 Oct 28;159(8):e54. doi: 10.1016/j.medcli.2022.04.018. Epub 2022 Jul 20.
2
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.托珠单抗对比标准治疗用于住院的中重度 COVID-19 肺炎成人患者的疗效。
Med Clin (Barc). 2022 Apr 8;158(7):301-307. doi: 10.1016/j.medcli.2021.03.005. Epub 2021 May 6.
3
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析，首次更新。
Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
4
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
5
Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.托珠单抗治疗 COVID-19 肺炎住院患者：随机对照试验的系统评价和荟萃分析。
J Investig Med. 2022 Jan;70(1):55-60. doi: 10.1136/jim-2021-002001. Epub 2021 Sep 24.
6
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.托珠单抗在住院的中重度 COVID-19 肺炎患者中联合或不联合皮质类固醇的实际应用：一项回顾性队列研究。
PLoS One. 2021 Sep 10;16(9):e0257376. doi: 10.1371/journal.pone.0257376. eCollection 2021.
7
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
8
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.COVID-19 病毒感染管理的 COVIRL002 试验-托珠单抗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
9
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.托珠单抗治疗重症 COVID-19 肺炎住院患者。
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
10
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.白细胞介素 6 阻断剂治疗 COVID-19：一项实时系统评价。
Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD013881. doi: 10.1002/14651858.CD013881.
本文引用的文献
1
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.早期使用依那西普联合可溶性尿激酶型纤溶酶原激活物受体血浆水平指导 COVID-19 治疗：一项双盲、随机对照 3 期试验。
Nat Med. 2021 Oct;27(10):1752-1760. doi: 10.1038/s41591-021-01499-z. Epub 2021 Sep 3.
2
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.托珠单抗对比标准治疗用于住院的中重度 COVID-19 肺炎成人患者的疗效。
Med Clin (Barc). 2022 Apr 8;158(7):301-307. doi: 10.1016/j.medcli.2021.03.005. Epub 2021 May 6.
3
Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.在患有严重SARS-CoV-2肺炎且炎症较轻的患者中，单独使用糖皮质激素与单独使用托珠单抗或糖皮质激素加托珠单抗的比较。
Med Clin (Engl Ed). 2021 Jun 25;156(12):602-605. doi: 10.1016/j.medcle.2021.01.004. Epub 2021 May 24.
4
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
5
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.托西珠单抗治疗嵌合抗原受体 T 细胞引起的细胞因子释放综合征。
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822. doi: 10.1080/1744666X.2019.1629904. Epub 2019 Jun 20.
Zotero 插件